Magnustropin specifically describes pharmaceutical human growth hormone that wassynthesized with the use of recombinant DNA technology. Magnustropin (rhGH) is biologicallyequivalent to human growth hormone (hGH) of pituitary origin.
Somatropin (rDNA origin) 3.33mg
Somatropin 10 IU (5 VIAL) + 5 x 1.5ml Bacteriostatic water
Magnustropin is considered to be a controversial anabolic and performance-enhancing drug inthe realm of bodybuilding and athletics. The main issue of debate is the exact level of potentialbenefit this substance carries. While studies with HIV+ patients in a wasting state tend to supportpotentially strong anabolic and anticatabolic properties, studies demonstrating these same effectsin healthy adults and athletes are lacking.
During the 1980s, a large body of myth surroundeddiscussions of hGH in bodybuilding circles, which may have been fueled by the high cost of thedrug and its very name (“growth hormone”). It was once thought to be the most powerful anabolicsubstance you could buy. Today, recombinant human growth hormone is much more affordableand readily obtained. Most experienced individuals now tend to agree that it is the fat-losspromoting properties of Magnustropin that are most obvious.
The drug can support musclegrowth, strength gains, and increased athletic performance, but its effects are generally milderthan those of anabolic/androgenic steroids. For a highly advanced athlete or bodybuilder,however, Magnustropin can help push body and performance further than might have beenpossible with steroids alone.
Magnustropin Side Effects
The most common adverse reactions to Magnustropin therapy are joint pain, headache, flu-likesymptoms, peripheral edema (water retention), and back pain. Less common adverse reactionsinclude inflammation of mucous membranes in the nose (rhinitis), dizziness, upper respiratoryinfection, bronchitis, tingling or numbness on the skin, reduced sensitivity to touch, generaledema, nausea, sore bones, carpal tunnel syndrome, chest pain, depression, gynecomastia,hypothyroidism, and insomnia.
The abuse of Magnustropin may cause diabetes, acromegaly (avisible thickening of the bones, most notably the feet, forehead, hands, jaw, and elbows), andenlargement of the internal organs. Due to the growth promotion effects of human growthhormone, this drug should not be used by individuals with active or recurring cancer.Magnustropin may reduce sensitivity to insulin and raise blood sugar levels. This may occur inindividuals without preexisting diabetes or impaired glucose tolerance.The subcutaneous administration of Magnustropin may cause redness, itching, or lumps at thesite of injection. It may also cause a localized decrease of adipose tissue, which may becompounded by the repeated administration at the same site of injection.
Magnustropin is designed for subcutaneous or intramuscular administration. One milligram ofMagnustropin is equivalent to approximately 3 International Units (3 IU). When used to treat adultonset growth hormone deficiency, the drug is commonly applied at a dosage of .005/mg/kg perday to .01mg/kg per day. This equates to roughly 1 IU to 3 IU per day for person of approximately180-220 lbs.
A long-term maintenance dosage is established after reviewing the patient’s IGF-1levels and clinical response over time.When used for physique- or performance-enhancing purposes, Magnustropin is usuallyadministered at a dosage between 1 IU and 6 IU per day (2-4 IU being most common). The drugis commonly cycled in a similar manner to anabolic/androgenic steroids, with the length of intakegenerally being between 6 weeks and 24 weeks. The anabolic effects of this drug are lessapparent than its lipolytic (fat loss) properties, and generally take longer periods of time andhigher doses to manifest themselves.
Other drugs are commonly used in conjunction with Magnustropin in order to elicit a strongerresponse. Thyroid drugs (usually T3) are particularly common given the known effects of Magnustropin on thyroid levels, and may significantly enhance fat loss during therapy. Insulin isalso commonly used with Magnustropin. Aside from countering some of the effects Magnustropinhas on glucose tolerance, insulin can increase receptor sensitivity to IGF-1, and reduce levels ofIGF binding protein-1, allowing for more IGF-1 activity (growth hormone itself also lowers IGFbinding protein levels).
Anabolic/androgenic steroids are also commonly taken with Magnustropin, in an effort to maximize potential muscle-building effects. Anabolic steroids may also furtherincrease free IGF-1 levels via a lowering of IGF binding proteins. Note that the stacking ofMagnustropin with thyroid drugs and/or insulin is usually approached with great care and caution,given that these are particularly strong medications with potentially serious or life threateningacute side effects.